Baicalein attenuates bleomycin-induced pulmonary fibrosis in rats through inhibition of miR-21

Baicalein attenuates bleomycin-induced pulmonary fibrosis in rats through inhibition of miR-21
复制标题

黄芩素通过抑制 miR-21 减轻博莱霉素诱导的大鼠肺纤维化

DOI:
10.1016/j.pupt.2013.03.006
复制
发表时间:
2013-12-01
影响因子:
3.2
通讯作者:
Jiang, Xiaogang
Jiang, Xiaogang
中科院分区:
医学3区
文献类型:
--
作者:
Gao, Yan;Lu, Jia;Jiang, Xiaogang

文献摘要

被引文献

相似文献

目前,肺纤维化尚无令人满意的治疗方法,迫切需要开发有效的药物。本研究的目的是探讨黄芩素对博来霉素诱导的肺纤维化的影响,以及抗纤维化作用的新机制。通过单次气管内滴注5mg/kg博来霉素诱导肺纤维化。两个博莱霉素治疗组从第 1 天到第 28 天每天口服 50 和 100 mg/kg 黄芩素。结果显示黄芩素降低了羟脯氨酸含量和 α-SMA 水平,并增加了肺指数。组织病理学检查显示黄芩素能明显降低肺泡炎和肺纤维化程度。经博莱霉素处理并添加黄芩素的大鼠的总抗氧化能力也显着高于未添加黄芩素的大鼠。在博来霉素治疗的大鼠中,黄芩素显着降低 miR-21 水平并抑制 TGF-β 1 和 p-Smad-2/3 表达的增加。黄芩素可以减轻博来霉素诱导的肺纤维化。这种减弱作用部分是通过提高抗氧化活性、减轻炎症、抑制 miR-21 和抑制 TGF-β/Smad 信号传导来实现的。 (C) 2013 Elsevier Ltd. 保留所有权利。
Currently, there is no satisfactory treatment for pulmonary fibrosis, and effective agents urgently need to be developed. The aim of the present study was to investigate the effects of baicalein on bleomycin-induced pulmonary fibrosis, and the novel mechanisms involved in the anti-fibrosis effects. Pulmonary fibrosis was induced by a single intratracheal instillation of 5 mg/kg bleomycin. Two bleomycin-treated groups were orally administered daily with 50 and 100 mg/kg of baicalein from day 1 to 28. The results showed baicalein decreased hydroxyproline content and alpha-SMA levels and increased lung index. Histopathological examinations demonstrated baicalein could obviously lower the degree of alveolitis and lung fibrosis. The total antioxidant capacity in bleomycin-treated rats with baicalein was also remarkably higher than in those without baicalein. Baicalein remarkably decreased miR-21 levels and inhibited the increased expression of TGF-beta 1 and p-Smad-2/3 in bleomycin-treated rats. Baicalein can attenuate bleomycin-induced pulmonary fibrosis. The attenuation is partly achieved by improving antioxidant activity, alleviating inflammation, repressing miR-21, and inhibiting TGF-beta/Smad signaling. (C) 2013 Elsevier Ltd. All rights reserved.